Prospectus Supplement No. 10
Filed Pursuant to Rule 424(b)(3)
File No. 333-269338
SeaStar Medical Holding Corporation
3513 Brighton Blvd,
Suite 410
Denver, CO 80216
(844) 427-8100
Prospectus Supplement No. 10
(to the Prospectus dated January 20, 2023)
This Prospectus
Supplement No. 10 supplements and amends the prospectus dated January 20, 2023, as amended by Prospectus Supplement No. 1 dated February 13, 2023, Prospectus Supplement No. 2 dated February 15, 2023, Prospectus Supplement No. 3
dated March 16, 2023, Prospectus Supplement No. 4 dated March 31, 2023, Prospectus Supplement No. 5 dated March 31, 2023, Prospectus Supplement No. 6 dated May 10, 2023. Prospectus Supplement No. 7 dated May 19, 2023,
Prospectus Supplement No. 8 dated May 23, 2023 and Prospectus Supplement No. 9 dated June 12, 2023 (the Prospectus), relating to the sale from time to time of up to 6,718,842 shares of our common stock by a selling shareholder.
On June 16, 2023, we filed with the U.S. Securities and Exchange Commission the attached Current Report on Form 8-K.
This Prospectus Supplement No. 10 should be read in conjunction with the Prospectus and is
qualified by reference to the Prospectus except to the extent that the information in this Prospectus Supplement No. 10 supersedes the information contained in the Prospectus.
Our common stock is traded on the Nasdaq Stock Market under the symbol ICU. On June 16, 2023, the last reported sale price of
our common stock was $0.54 per share.
Investing in our common stock involves a high degree of risk. See Risk Factors beginning on page 8 of the Prospectus dated January
20, 2023.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these
securities or determined if this Prospectus Supplement No. 10 is truthful or complete. Any representation to the contrary is a criminal offense.
The date of this
Prospectus Supplement No. 10 is June 21, 2023.